Clinical Trial

NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of antidepressant nonresponders with MDD.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-11-16; most recent amendment 2025-02-16.
Status change: Not Yet Recruiting → Recruiting 2022-01-25
Trial Details
NCT Number NCT05136755
Lead Sponsor China Medical University Hospital
Conditions Major Depressive Disorder
Enrollment 50 participants
Start Date 2022-01-25
Primary Completion 2026-11 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-02-19